Trials / Completed
CompletedNCT01130077
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas
A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides with Poly-ICLC for Children with Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- James Felker · Academic / Other
- Sex
- All
- Age
- 12 Months – 21 Years
- Healthy volunteers
- Not accepted
Summary
The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.
Conditions
- Newly Diagnosed Pediatric Pontine Glioma
- Newly Diagnosed Pediatric High Grade Glioma
- Recurrent Pediatric High Grade Glioma
- Recurrent Pediatric Low Grade Glioma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HLA-A2 restricted glioma antigen peptides vaccine | Vaccine given every 3 weeks |
| BIOLOGICAL | Poly-ICLC | Vaccine given every 3 weeks |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
- First posted
- 2010-05-25
- Last updated
- 2024-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01130077. Inclusion in this directory is not an endorsement.